Höhere Feldstärken in der kardiovaskulären MRT

Abstract

Today Cardiovascular Magnetic Resonance at 1,5 Tesla has a defined place in clinical cardiology routine assessment. That depends on availability and investigator experience. The role of higher field strengths in clinical routine is under investigation. One can expect, that a selected, focused application will provide an added value. That will depend on the provided diagnostic accuracy and an improvement of scan comfort itself (e. g. scan-time and patient comfort)

In summary, higher field strengths itself cannot guarantee an improved diagnostic accuracy in cardiology. Already today, CMR itself can provide a reliable and unique diagnosis in clinical routine.

Literatur

• 1 Deutsche Kardiologische Gesellschaft . Klinische Indikationen für die kardiovaskuläre Magnetresonanztomographie(CMR).  Clin Res Cardiol Suppl. 2007;  2 77-96
• 2 Pettigrew R I. Dynamic cardiac MR imaging. Techniques and applications.  Radiol Clin North Am. 1989;  27 1183-1203
• 3 Kollia K, Maderwald S, Putzki N. et al . First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5 T and 7 T.  AJNR Am J Neuroradiol. 2009;  30 699-702
• 4 Friedrich M G, Abdel-Aty H, Taylor A. et al . The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance.  JACC. 2008;  51 1581-1587
• 5 Aletras A, Tilak G S, Natanzon A. et al . Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations.  Circulation. 2006;  113 1865-1870
• 6 Bruder O, Schneider S, Nothnagel D. et al . EuroCMR (European Cardiovascular Magnetic Resonance) Registry Results of the German Pilot Phase.  J Am Coll Cardiol. 2009;  15 1452-1466
• 7 Schulz-Menger J, Wassmuth R, Abdel-Aty H. et al . Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance.  Heart. 2006;  92 399-400
• 8 Maceira A M, Joshi J, Prasad S K. et al . Cardiovascular magnetic resonance in cardiac amyloidosis.  Circulation. 2005;  111 186-183
• 9 Becker M, Frauenrath T, Hezel F. et al . Comparison of left ventricular function assessment using phonocardiogram- and electrocardiogram-triggered 2D SSFP CINE MR imaging at 1.5 T and 3.0 T.  Eur Radiol. 2009;  5 344-355
• 10 Anderson L J, Wonke B, Prescott E. et al . Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.  Lancet. 2002;  360 516-520
• 11 Gutberlet M, Noeske R, Schwinge K. et al . Comprehensive cardiac magnetic resonance imaging at 3.0 Tesla: feasibility and implications for clinical applications.  Invest Radiol. 2006;  41 154-167
• 12 Snyder C J, DelaBarre L, Metzger G J. et al . Initial results of cardiac imaging at 7 Tesla.  Magn Reson Med. 2009;  61 517-524
• 13 von Knobelsdorff-Brenkenhoff F, Frauenrath T, Prothmann M. et al . Cardiac chamber quantification using magnetic resonance imaging at 7 Tesla – a pilot study.  Eur Radiol. 2010;  17 (epub ahead of print)